Newron Pharmaceuticals S.p.A.
NP5
Pozycja w akcjach
#17660
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Cena akcji
$10.77
Kapitalizacja rynkowa
$220.23M
Zmiana (1 dzień)
1.34%
Zmiana (1 rok)
-38.60%
Kraj
IT
Handel Newron Pharmaceuticals S.p.A. (NP5)
Kategoria
Healthcare
Historia stopy dywidendy dla Newron Pharmaceuticals S.p.A. (NP5)
Stopa dywidendy (TTM) dla Newron Pharmaceuticals S.p.A. (symbol akcji: NP5) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Newron Pharmaceuticals S.p.A. (NP5) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
| Rok | Stopa dywidendy | Zmień |
|---|---|---|
| Za mało danych dla podanych dat. | ||
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
| Firma | Stopa dywidendy | Kraj |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
